Q3 EPS Estimates for Palisade Bio Cut by Analyst

Palisade Bio, Inc. (NASDAQ:PALI) – Research analysts at Brookline Capital Markets decreased their Q3 2026 earnings per share (EPS) estimates for Palisade Bio in a note issued to investors on Friday, August 14th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.06) per share for the quarter, down from their prior estimate of ($0.05). The consensus estimate for Palisade Bio’s current full-year earnings is ($0.22) per share. Brookline Capital Markets also issued estimates for Palisade Bio’s Q4 2026 earnings at ($0.06) EPS, FY2026 earnings at ($0.21) EPS, FY2027 earnings at ($0.23) EPS, FY2028 earnings at ($0.27) EPS and FY2029 earnings at ($0.38) EPS.

A number of other brokerages have also recently commented on PALI. Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target on shares of Palisade Bio in a research note on Tuesday, June 30th. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Finally, Oppenheimer started coverage on Palisade Bio in a research note on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $9.00.

Palisade Bio Stock Up 0.5%

NASDAQ PALI opened at $2.15 on Tuesday. The stock has a market cap of $374.68 million, a P/E ratio of -2.13 and a beta of 1.52. The company’s 50-day simple moving average is $1.96 and its 200 day simple moving average is $1.92. Palisade Bio has a twelve month low of $0.53 and a twelve month high of $2.86.

Palisade Bio (NASDAQ:PALI) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $0.50 million during the quarter, compared to the consensus estimate of $0.50 million.

Hedge Funds Weigh In On Palisade Bio

Several large investors have recently bought and sold shares of PALI. Cetera Investment Advisers bought a new stake in shares of Palisade Bio during the 4th quarter valued at $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC bought a new position in shares of Palisade Bio during the 4th quarter valued at about $28,000. Legal & General Group Plc acquired a new position in shares of Palisade Bio in the 2nd quarter valued at approximately $30,000. Finally, CTC Alternative Strategies Ltd. bought a new stake in Palisade Bio during the 1st quarter worth approximately $31,000. 11.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Palisade Bio news, insider Mitchell Lawrence Jones sold 51,880 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $2.05, for a total transaction of $106,354.00. Following the completion of the sale, the insider directly owned 94,009 shares of the company’s stock, valued at approximately $192,718.45. The trade was a 35.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO John David Finley sold 146,798 shares of the company’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.07, for a total transaction of $303,871.86. Following the transaction, the chief executive officer owned 217,555 shares in the company, valued at approximately $450,338.85. The trade was a 40.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders bought a total of 125,000 shares of company stock worth $250,100 over the last three months. 0.07% of the stock is currently owned by company insiders.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.